Research at Bristol Myers Squibb Co. has led to the development of [11]-carbon-labeled compounds targeting Bruton tyrosine kinase (BTK) as positron emission tomography (PET) imaging agents for the diagnosis of multiple sclerosis.
2,4-Dihydro-3h-1,2,4-triazol-3-one P2X7 receptor antagonists have been reported in an Axxam SpA patent as potentially useful for the treatment of cognitive, eye, gastrointestinal, genitourinary and psychiatric disorders, chronic pain, neuropathic pain and neurodegeneration.
Institute of Rheological Function of Food Co. Ltd. and Kyushu University have synthesized plasmalogen derivatives reported to be useful for the treatment of dementia, Rett syndrome, Parkinson’s disease, depression and schizophrenia.
Facioscapulohumeral muscular dystrophy (FSHD) is a skeletal muscular dystrophy characterized by DNA hypomethylation of D4Z4 repeat units of a macrosatellite array found at the distal end of chromosome region 4q35, which causes a myotoxic expression of DUX4. Researchers from Epic-Bio presented the discovery of EPI-321, a novel gene therapy candidate for the treatment of FSHD.
When tissue injury occurs, stressed cells release a bunch of intracellular molecules called damage-associated molecular pattern (DAMP) proteins. S100 calcium binding protein A9 (S100A9) is a DAMP usually found in macrophages and is involved in multiple inflammatory responses, such as activation of Toll-like receptor 4 (TLR4).
RSS
